EMA Authorised: Adempas (riociguat) — Bayer AG

View source ↗

Summary

EMA authorised Adempas (riociguat) by Bayer AG for pulmonary hypertension indications, with a decision dated 06/08/2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension
• Thromboembolic Pulmonary Hypertension

Drugs mentioned

• Adempas (riociguat)

Snippet

Status: Authorised. Therapeutic area: Hypertension, Pulmonary. MAH: Bayer AG. Decision date: 06/08/2025